The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sergeeva M.S.

Krasnov Research Institute of Eye Diseases

Danilov S.S.

Krasnov Research Institute of Eye Diseases

Sherbakova N.I.

P. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Ocular myasthenia gravis

Authors:

Sergeeva M.S., Danilov S.S., Sherbakova N.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2024;140(4): 86‑91

Read: 2227 times


To cite this article:

Sergeeva MS, Danilov SS, Sherbakova NI. Ocular myasthenia gravis. Russian Annals of Ophthalmology. 2024;140(4):86‑91. (In Russ.)
https://doi.org/10.17116/oftalma202414004186

Recommended articles:
Comparison of mate­rials used in upper eyelid ptosis surgery. Plastic Surgery and Aesthetic Medi­cine. 2024;(4-2):67-71

References:

  1. Kuzin MI, Gekht BM. Myasthenia. M.: Medicine; 1996;224. (In Russ.).
  2. Sanadze AG. Myasthenia gravis and myasthenic syndromes: a guide. M.: Litterra; 2012;255. (In Russ.).
  3. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52: 90-100.  https://doi.org/10.1016/j.jaut.2013.12.011
  4. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. J Neuromuscul Dis. 2015;2(1):73-85. 
  5. Abukhalil F, Mehta B, Saito E, Mehta S, McMurtray A. Gender and ethnicity based differences in clinical and laboratory features of Myasthenia Gravis. Autoimmune Dis. 2015;2015:197893. https://doi.org/10.1155/2015/197893
  6. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.  https://doi.org/10.1186/1471-2377-10-46
  7. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.  https://doi.org/10.1002/mus.20950
  8. Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14(5):516-519.  https://doi.org/10.1002/ana.410140504
  9. Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988;77(1):31-35.  https://doi.org/10.1111/j.1600-0404.1988.tb06970.x
  10. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16-23.  https://doi.org/10.1212/wnl.55.1.16
  11. Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev. 2013;12(9):924-930.  https://doi.org/10.1016/j.autrev.2013.03.002
  12. Sommer N, Tackenberg B, Hohlfeld R. The immunopathogenesis of myasthenia gravis. Handb Clin Neurol. 2008;91:169-212.  https://doi.org/10.1016/S0072-9752(07)01505-9
  13. Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012;69(8):994-1001. https://doi.org/10.1001/archneurol.2012.437
  14. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875-884.  https://doi.org/10.1016/j.autrev.2013.03.007
  15. Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12(9):931-935.  https://doi.org/10.1016/j.autrev.2013.03.004
  16. Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123(12): 5190-5202. https://doi.org/10.1172/JCI66039
  17. Al-Haidar M., Benatar M, Kaminski HJ. Ocular Myasthenia. Neurol Clin. 2018;36(2):241-251.  https://doi.org/10.1016/j.ncl.2018.01.003
  18. Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014;13(10):1003-1007. https://doi.org/10.1016/j.autrev.2014.08.039
  19. Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci. 2003;998:362-374.  https://doi.org/10.1196/annals.1254.043
  20. Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis? Neurology. 1990;40(11):1663-1669. https://doi.org/10.1212/wnl.40.11.1663
  21. Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, Dimachkie M. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis. 2011;13(1):46-52.  https://doi.org/10.1097/cnd.0b013e31821c5634
  22. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89(10):1330-1334. https://doi.org/10.1136/bjo.2004.063404
  23. Akan O, Baysal-Kirac L. Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis. Acta Neurol Belg. 2021;121(5):1131-1140. https://doi.org/10.1007/s13760-020-01556-3
  24. Elrod RD, Weinberg DA. Ocular myasthenia gravis. Ophthalmol Clin North Am. 2004;17(3):275-309.  https://doi.org/10.1016/j.ohc.2004.05.014
  25. Cogan DG. Myasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign. Arch Ophthalmol. 1965;74:217-221.  https://doi.org/10.1001/archopht.1965.00970040219016
  26. Averbuch-Heller L, Poonyathalang A, von Maydell RD, Remler BF. Hering’s law for eyelids: still valid. Neurology. 1995;45(9):1781-1783. https://doi.org/10.1212/wnl.45.9.1781-a
  27. Fakiri MO, Tavy DL, Hama-Amin AD, Wirtz PW. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve. 2013;48(6):902-904.  https://doi.org/10.1002/mus.23857.
  28. Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to Tensilon. J Clin Neuroophthalmol. 1991;11(04): 288-292. 
  29. Pruitt JA, Ilsen P. Ocular manifestations of myasthenia gravis. In: Pruitt JA, ed. A Look into Myasthenia Gravis. InTech; 2012;15-20.  https://doi.org/10.5772/30168
  30. Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol. 2014;62(10):985-991.  https://doi.org/10.4103/0301-4738.145987
  31. Liu GT, Volpe NJ, Galetta S. Neuro-Ophthalmology: Diagnosis and Management. Amsterdam: Elsevier; 2018;29. 
  32. Pelak VS, Galetta SL. Ocular Myasthenia Gravis. Curr Treat Options Neurol. 2001;3(4):367-376.  https://doi.org/10.1007/s11940-001-0040-7
  33. Cooper J, Pollak GJ, Ciuffreda KJ, Kruger P, Feldman J. Accommodative and vergence findings in ocular myasthenia: a case analysis. J Neuroophthalmol. 2000;20(1):5-11.  https://doi.org/10.1097/00041327-200020010-00003
  34. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015;15(3):199-206.  https://doi.org/10.1136/practneurol-2015-001126
  35. Clinical guidelines for the diagnosis and treatment of myasthenia gravis. All-Russian Society of Neurologists. M. 2016;28. (In Russ.).
  36. Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017;17(1):77.  https://doi.org/10.1186/s12883-017-0857-7
  37. Mercelis R, Merckaert V. Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia. Muscle Nerve. 2011;43(2):168-170.  https://doi.org/10.1002/mus.21853
  38. O’Hare M, Doughty C. Update on Ocular Myasthenia Gravis. Semin Neurol. 2019;39(6):749-760.  https://doi.org/10.1055/s-0039-1700527
  39. Wong SH, Petrie A, Plant GT. Ocular Myasthenia Gravis: Toward a Risk of Generalization Score and Sample Size Calculation for a Randomized Controlled Trial of Disease Modification. J Neuroophthalmol. 2016;36(3):252-258.  https://doi.org/10.1097/WNO.0000000000000350
  40. Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018 Jn;128(1):15-24.  https://doi.org/10.1080/00207454.2017.1344237
  41. Alekseeva TM, Gavrilov YV, Kreis OA, Valko PO, Weber KP, Valko Y. Fatigue in patients with myasthenia gravis. J Neurol. 2018;265(10):2312-2321. https://doi.org/10.1007/s00415-018-8995-4
  42. Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve. 2021;63(5):631-639.  https://doi.org/10.1002/mus.27118.
  43. Shcherbakova NI. Pathogenetic rationale for the strategy and tactics of treating myasthenia gravis: Dis. ... d-ra. med. nauk. M. 2008. (In Russ.).
  44. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314-1320. https://doi.org/10.1007/s00415-009-5120-8
  45. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131-133.  https://doi.org/10.1016/j.jns.2003.08.017
  46. Guidon AC, Hobson-Webb LD. On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness. Muscle Nerve. 2018;58(6):743-744.  https://doi.org/10.1002/mus.26317
  47. Haines SR, Thurtell MJ. Treatment of ocular myasthenia gravis. Curr Treat Options Neurol. 2012;14(1):103-112.  https://doi.org/10.1007/s11940-011-0151-8
  48. Benatar M., Kaminski H. (2005) Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. Epub 2005 Jan 24 [Preprint]. https://doi.org/10.1002/14651858.cd005081
  49. Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687-693.  https://doi.org/10.1111/ene.12359
  50. Peragallo JH, Velez FG, Demer JL, Pineles SL. Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis. J Neuroophthalmol. 2013;33(1):40-44.  https://doi.org/10.1097/wno.0b013e318280d630
  51. Wolfe GI, Kaminski HJ, Aban IB, et al; MGTX Study Group. Longterm effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2- year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259-268.  https://doi.org/10.1016/S1474-4422(18)30392-2
  52. Wolfe GI, Kaminski HJ, Sonnett JR, Aban IB, Kuo HC, Cutter GR. Randomized trial of thymectomy in myasthenia gravis. J Thorac Dis. 2016;8(12): E1782-E1783. https://doi.org/10.21037/jtd.2016.12.80
  53. Gilbert ME, De Sousa EA, Savino PJ. Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy. Arch Neurol. 2007; 64(12):1790-1792. https://doi.org/10.1001/archneur.64.12.1790

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.